1
Gout-Zwart, Judith J., de Jong, Lisa A., Saptenno, Lisanne, Postma, Maarten J
Veröffentlicht in: Gout-Zwart , J J , de Jong , L A , Saptenno , L & Postma , M J 2020 , ' Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The Netherlands ' , PharmacoEconomics - open , vol. 4 , no. 2 , pp. 321-330 . https://doi.org/10.1007/s41669-019-00179-6;
2020
Veröffentlicht in: Gout-Zwart , J J , de Jong , L A , Saptenno , L & Postma , M J 2020 , ' Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The Netherlands ' , PharmacoEconomics - open , vol. 4 , no. 2 , pp. 321-330 . https://doi.org/10.1007/s41669-019-00179-6;
2020
2
de Jong, Lisa Aniek, Gout-Zwart, Judith J, van den Bosch, Marina, Koops, Mike, Postma, Maarten J
Veröffentlicht in: de Jong , L A , Gout-Zwart , J J , van den Bosch , M , Koops , M & Postma , M J 2019 , ' Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands : a real-world data based cost-effectiveness analysis ' , Journal of Medical Economics , vol. 22 , no. 4 , pp. 306-318 . https://doi.org/10.1080/13696998.2018.1563404;
2019
Veröffentlicht in: de Jong , L A , Gout-Zwart , J J , van den Bosch , M , Koops , M & Postma , M J 2019 , ' Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands : a real-world data based cost-effectiveness analysis ' , Journal of Medical Economics , vol. 22 , no. 4 , pp. 306-318 . https://doi.org/10.1080/13696998.2018.1563404;
2019